Therapeutic Response

BRAF p.V600K status confers therapeutic sensitivity to Vemurafenib in patients with Melanoma.

View API

Statements

Source and description
Zelboraf (vemurafenib) [product monograph]. HC.

Health Canada approved vemurafenib as a monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. A validated test is required to identify BRAF V600 mutation status.

View API